The 18th version of CPHI & PMEC India, organised by Informa Markets in India, commenced on the India Expo Centre, Larger Noida, Delhi-NCR, showcasing the sturdy potential of India’s pharmaceutical business. Bringing collectively over 2,000 exhibitors and 50,000 guests from greater than 120 international locations, together with China, Italy, Germany, Switzerland, and South Korea, the expo served as a dynamic hub for innovation and collaboration. Spanning pharma equipment, packaging, analytical devices, lab & analytical gear, cleanroom know-how, laboratory applied sciences, substances, and past, it gives a complete platform for stakeholders to have interaction in transformative dialogues and foster strategic partnerships.
From 2026 onward, CPHI and PMEC India will transition into two specialised reveals throughout two areas on consecutive days, a call formed by in depth stakeholder suggestions. This shift is designed to present every platform the house, focus, and depth it deserves: CPHI at Dwarka will provide a extra premium, content-driven setting, whereas PMEC at IEML will deal with scale necessities and supply an optimised expertise for equipment and know-how exhibitors.
Within the present version, the grand inauguration was graced by an esteemed lineup of business leaders, policymakers, and international representatives. The distinguished company included Mr. Ok. Raja Bhanu, Director Normal, Pharmexcil; Dr. R Chandrashekar, Joint Medication Controller, CDSCO; Mr. Harish Ok Jain, President, FOPE; Mr. Namit Joshi, Chairman, Pharmexcil; Mr. Kaushik Desai, Secretary Normal, IPEC India and HADSA; Mr. Rakesh Kumar, Chairman, India Expo Mart Restricted (IEML); Mr. Satyaprakash TL, Joint Secretary, Division of Prescribed drugs, Govt of India; Dr. Jitendra Kumar, Managing Director, BIRAC, Division of Biotechnology (DBT), Authorities of India; Sri Ch A P Rameswara Rao, Nationwide President, BDMAI; Mr. Anil Matai, Director Normal, OPPI; Mr. Sudarshan Jain, Secretary-Normal, Indian Pharmaceutical Alliance; and Mr. AVPS Chakravarthi, Ambassador, WPO; Mr. Yogesh Mudras, Managing Director, Informa Markets in India; Mr. Rahul Deshpande, Sr. Group Director, Informa Markets in India; and Mr. Orhan Caglayan, Govt Vice President – Pharma, Informa Markets B.V; who did the honours, amidst an august business presence.
Talking on the occasion Mr. Namit Joshi, Chairman, Prescribed drugs Export Promotion Council of India (Pharmexcil), mentioned, “The worldwide pharmaceutical panorama is shifting quickly, and India should evolve past its conventional generics mindset to stay the pharmacy of the world. The longer term lies in value-driven innovation—advancing capabilities in peptides, complicated generics, biosimilars, biologics, focused drug supply methods, and cell and gene therapies. Breakthrough lessons resembling GLP-1 inhibitors are redefining international well being outcomes, and Indian producers are already making ready to enter these high-value segments as patents expire. Whereas constructing scale in these superior areas will take the following 5 to 6 years, many Indian corporations have already taken sturdy steps ahead. What the business now wants is broader considering, cross-domain insights, and a extra innovation-led method to strengthen India’s function in shaping the following period of worldwide healthcare.”
Dr. R Chandrashekar Joint Medication Controller, The Central Medication Commonplace Management Organisation (CDSCO), mentioned “India’s pharmaceutical sector is quickly shifting from a generics-led basis to an innovation-driven ecosystem, with rising emphasis on biosimilars, peptides, complicated generics, and next-generation biologics. This transition is being accelerated by authorities and CDSCO reforms resembling streamlined approvals, diminished regulatory layers, decriminalisation of non-serious offences, and the advice of R&D tasks price ₹5,000 crore. The newly launched Hospital Finance scheme of ₹1,00,000 crore additional strengthens the nation’s R&D panorama. With these measures, India is well-positioned to evolve from being the pharmacy of the world to an innovation-led pharma nation over the following 5 years.”
Mr. Anil Matai, Director Normal, Organisation of Pharmaceutical Producers of India (OPPI), mentioned “After firmly establishing itself because the ‘Pharmacy to the World,’ the nation is now transitioning towards turning into a real pharma powerhouse. This shift is supported by enabling rules, improved processes, and a rising emphasis on innovation, stronger mental property safety, and the elimination of patent infringements. These reforms mirror the federal government’s broader imaginative and prescient to ‘uncover in India, innovate in India, and innovate for the world,’ and the primary steps towards that future are already seen. The following 5 years will look very completely different from the final, pushed by higher funding in innovation and a deeper dedication to patient-centricity. Whereas remoted high quality lapses have occurred, the business stays targeted on strengthening safeguards to make sure such incidents don’t recur, defending each affected person belief and India’s international status.”
Mr. Harish Ok Jain, President, Federation of Pharma Entrepreneurs (FOPE), mentioned “India’s pharma business is present process a serious shift from a purely generics-driven mannequin to 1 rooted in ‘Navachar and Anusandhan’—innovation and analysis. Whereas the sector contains a number of the nation’s largest corporations, a good portion contains MSMEs, and they’re equally a part of this transformation. Many MSME members are showcasing their new applied sciences and modern merchandise at this exhibition, demonstrating how actively they’re contributing to India’s evolving pharma panorama. Over time, a number of MSMEs that when began small at CPHI have grown to export to greater than 100 international locations. This progress displays the altering route of the nation and the rising power of India’s innovation-led pharmaceutical ecosystem.”
Mr. Kaushik Desai, Secretary Normal, Worldwide Pharmaceutical Excipients Council of India (IPEC) and HADSA, mentioned “The occasion serves as a major gateway for worldwide guests and exporters to discover India’s full spectrum of innovation from supplies and providers to superior equipment and a powerful excipient ecosystem that alone represents a USD 1 billion business. India’s pharmaceutical sector at the moment a USD 30 billion export market with an analogous home measurement has the potential to scale to USD 130 billion by 2030 and attain USD 450 billion by 2047. To attain this, authorities insurance policies should maintain tempo with international developments, particularly in innovation. Whereas new initiatives like PRPI are welcome, stronger monitoring and accountability throughout stakeholders are important to make sure actual outcomes. Solely then can India totally realise its development potential slightly than merely discuss it.”
Mr. Sudish Sukumaran, Emach Packages, mentioned “India’s pharmaceutical packaging equipment business is increasing steadily, pushed by a balanced mixture of home demand and exports every contributing considerably to the nation’s USD 25 billion pharma export market. For over 35 years, we’ve got seen constant development in oral strong packaging, with India now rising as a key international hub. As one of many world’s largest producers of blister packaging machines exterior of China, we produce round 225–250 machines yearly, almost 1 / 4 of the worldwide market of about 1,000 machines. About 70% of our volumes cater to India, whereas 30% are exported, supported by our expanded footprint within the U.S. and Europe by means of strategic acquisitions.
The market is now being reshaped by rising demand in power therapies, life-style ailments, nutraceuticals, and specialised segments like oncology, which require high-containment and precision gear. Classes resembling anti-cancer packaging have grown almost five-fold within the final three years. As affected person volumes rise and well being consciousness will increase, the necessity for superior, high-efficiency, and compliant packaging equipment will proceed to surge. Our business is rising at 16–20% yearly, reflecting broader sectoral momentum.”
Dr. Sridevi Khambhampaty, CEO, Shilpa Biologicals, mentioned “Biologics is coming into an thrilling section with Europe and the US easing biosimilar rules, together with waivers for Section 3 trials. That is decreasing entry limitations for Indian gamers and accelerating biosimilar improvement. Moreover, the biologics business in India has matured during the last decade and is now able to step into modern biologics. At Shilpa Biologicals, we’re advancing partnerships in Switzerland and the US to deliver novel biologics to market, whereas strengthening our biosimilars portfolio. We hope to develop our biosimilars portfolio considerably to deliver greater than 6 merchandise within the subsequent 4 years. Whereas competitors exists, biopharma stays a distinct segment house with solely a handful of succesful gamers given the funding and expertise required.”
Highlighting the importance of this 12 months’s CPHI & PMEC India Expo, Mr. Yogesh Mudras, Managing Director, Informa Markets in India, mentioned, “India’s pharmaceutical sector has achieved outstanding development, with exports doubling to USD 30 billion and almost half of worldwide life sciences leaders establishing operations right here. We’re witnessing a robust transformation as India strengthens its footprint throughout conventional generics, complicated formulations, biologics, and superior therapies. This 12 months’s sturdy worldwide participation at CPHI & P-MEC India demonstrates international confidence in India’s innovation capabilities. Having reached the head of success with the present, our technique of organising separate CPHI and PMEC codecs in India will ship much more targeted and impactful conversations, focusing on, and extra significant enterprise journeys.”
The occasion featured participation from main corporations resembling Dr. Reddy’s Laboratories Ltd., Hetero Labs, Oceanic Pharmachem, Akums Medication & Prescribed drugs, Morepen Laboratories, MSN Laboratories, Capsugel Healthcare, Biocon, and Jubilant Ingrevia. On the equipment aspect, PMEC India featured prime gamers together with ACG Pam Pharma Applied sciences, Cadmach Equipment, Ace Applied sciences & Packaging Techniques, Parle International Applied sciences, Klenzaids Contamination Controls, Gansons, Elmach Packages, Shimadzu India, and Snowbell Machines.
This 12 months, the expo garnered sturdy help from key business associations resembling Pharmexcil, Worldwide Pharmaceutical Excipients Council (IPEC) India, Bulk Drug Producers Affiliation of India (BDMAI), and Organisation of Pharmaceutical Producers of India (OPPI), Federation of Pharma Entrepreneurs (FOPE) and The Indian Pharmaceutical Affiliation (IPA) together with participation from regulatory authorities and policymakers.
